Cannabis Law Report

JUNE 4, 2021

Nasdaq: AIKI ) (“AIkido” or the “Company”) today announced that positive Phase 1 testing data was presented at the 2021 ASCO Annual Meeting June 4 , 2021. Additionally, this novel antibody conjugate demonstrated very good tolerability during this DLT phase 1 trial. About AIkido Pharma Inc. AIkido Pharma Inc.

Data 100

Data Research and Development Clinical Trials Therapy 100

The Cannigma

FEBRUARY 1, 2023

Unlike healthy cells, these abnormal cells don’t die as they are typically programmed to do, and instead begin to grow and divide uncontrollably, effectively circumventing the body’s normal checks and balances. To date, very few human clinical trials have been conducted to assess the effectiveness of THC or CBD in treating cancer.

Clinical Trials 145

Clinical Trials Research and Development Therapy Cannabinoids 145

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

DECEMBER 27, 2019

Virtual Clinical Trials transcend geographic, mobility and economic barriers. Clinical trials are medical research projects involving human participants. However, the costs of conducting a full-scale clinical trial can be prohibitive, posing barriers to research for cannabis companies.

Clinical Trials 85

Clinical Trials Access Research and Development Supply Chain 85

Cannabis Law Report

DECEMBER 7, 2021

Ibogaine is not the ideal addiction-treatment drug; it can cause cardiac arrhythmia (an irregular heartbeat) and its intense psychedelic experience is not for everyone. Food and Drug Administration to launch human clinical trials. All testing is conducted under blinded conditions and all data is confidential.

Treatment 52

Treatment Clinical Trials Data Conditions 52

Cannabis Law Report

JUNE 19, 2022

Unlike novel chemical compounds that are synthetically produced in the pharmaceutical industry through drug development programs, psychedelic compounds have a long and established history. As we see more data emerge from clinical trials, we are likely to see patent applications covering stability, pharmacokinetic, and pharmacodynamic data.

Clinical Trials 52

Clinical Trials Microdosing Data Pharmaceutical 52

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

MAY 10, 2022

First academic study of national medicinal cannabis data. The first in-depth study of Australia’s medicinal cannabis program, which began in 2016, shows the drug is being increasingly prescribed for various conditions. Since the beginning of the program, medicinal cannabis has been prescribed for over 140 conditions.

Medicine 52

Medicine Clinical Trials Sleep Data 52

Puff Puff Post

SEPTEMBER 16, 2019

16, 2019 /CNW/ – Québec doctors have a new tool at their disposal for learning about medical cannabis and its viability as a treatment option for their patients. The program will be offered for free to Québec physicians and is made possible by an unrestricted educational grant from Spectrum Therapeutics.

Programs 108

Programs Research and Development Education Treatment 108

Cannabis Law Report

MAY 10, 2022

Anxiety and sleep disorders were some reasons given for prescriptions despite lack of evidence for cannabis treatment, researchers find. The data also shows that prior to 2020, people between 45 and 52 years old had the highest incidence of prescriptions. We are aware of clinical trials in that space, but not strong evidence.”.

Medicine 52

Medicine Clinical Trials Data Sleep 52

Puff Puff Post

DECEMBER 28, 2018

An official study is aimed to conclude in July of 2019, where we’ll see all the data which comes forth. The Current Treatments for Autism. Most education-based autism treatment is focused on teaching developing children self-care, communicative, and social skills. As it sits, only a few methods of treating autism are available.

Treatment 76

Treatment Oil CBD Therapy 76

SpeedWeed

SEPTEMBER 17, 2021

The funding will allow MAPS Public Benefit Corporation (MAPS PBC) to activate a team to evaluate the scope of the lack of resources needed for TBI treatment. . Data collected from MAPS-sponsored Phase 3 clinical trials suggests that MDMA-assisted therapy appears promising in the treatment of TBI.

Clinical Trials 53

Clinical Trials Research and Development Therapy Treatment 53

Cannabis Law Report

DECEMBER 26, 2021

In furtherance of its program, the Company filed US Provisional Patent Application No. “Entheon is proud to be making significant strides in its Entheon IQ™ program,” says Timothy Ko, Chief Executive Officer of Entheon. EBRX-101 on Track to Submit Regulatory Package for Human DMT Clinical Trial.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

NORML

JANUARY 28, 2019

It’s understandable lawmakers want reliable data before making a decision. The good news for Kentucky legislators is the data already i s available. The National Center for Biotechnology Information has summarized a group of FDA approved randomized clinical trials, finding evidence for cannabis as medicine.

Data 188

Data Clinical Trials Chronic Pain Medicine 188

SpeedWeed

MAY 22, 2021

The US Food and Drug Administration (FDA) has just approved a new clinical trial that will allow therapists to legally use MDMA. For this Phase 1 trial, MAPS will recruit 150 therapists that are currently being trained to conduct MDMA-assisted therapy sessions for PTSD. .

Clinical Trials 52

Clinical Trials Therapy Legalization Research and Development 52

SpeedWeed

AUGUST 11, 2021

Suicide among veterans is an urgent public health crisis, but it’s solvable if we invest in researching new treatments for pain, depression, and PTSD,” said Sisley in a press statement. The grant comes from Michigan’s 2021 Veteran Marijuana Research Grant Program , and is funded by the state’s recreational cannabis taxes.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical DEA 52

Veriheal

MAY 26, 2022

Of course, legalization and education efforts can only go so far without data, and that’s where RoC’s research initiatives come into play. In addition to the large uptick in registrants, we saw an even larger influx of new visitors to our site, enabling them to learn more about our research program.”.

Advocacy 98

Advocacy Patients Clinical Trials Education 98

Cannabis Law Report

NOVEMBER 22, 2021

The small company has seven patient-treating clinics around Australia which it uses to progress the development and registration of new drugs. In light of the evidence and the growing recognition of major mental health disorders and the need for more treatment options. Read more [link].

Clinical Trials 52

Clinical Trials Treatment Medicine Cannabinoids 52

Cannabis Law Report

JANUARY 31, 2022

This list is available by request to those seeking access to psilocybin through the Special Access Program (SAP), and clinical researchers. Earlier this month, Health Canada added certain psychedelic compounds to the SAP that were previously available only through clinical trials.

Research and Development 52

Research and Development Clinical Trials Packaging Access 52

Cannabis Law Report

JULY 28, 2021

Validates Cepharanthine’s potential in treating various cancers with unsatisfactory treatment options. Advance to FDA IND-enabling studies to support human clinical studies. Previously the Company announced that it had secured FDA Orphan Drug Designation for cepharanthine in the treatment of esophageal cancer.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

JANUARY 24, 2022

Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. Tucker brings to Goldfinch Bio over 30 years of clinical experience across a variety of therapeutic areas and early- and late-stage companies. CAMBRIDGE, Mass.–(BUSINESS

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Cannabis Law Report

NOVEMBER 26, 2021

With the anticipated launch of Pfizer’s oral COVID-19 antiviral drug candidate, Can-Fite has made a strategic decision to end its COVID-19 program and to focus its resources on its other clinical programs, all in advanced clinical trials. Fortified Balance Sheet. Financial Results.

Clinical Trials 52

Clinical Trials Research and Development Treatment Data 52

Cannabis Law Report

NOVEMBER 12, 2021

Completed manufacturing of ANEB-001 capsules for upcoming Phase 2 clinical trial. In August Anebulo formed the SAB to advise the Company on its clinical development programs and product pipeline. Condensed Balance Sheet Data. . . The founding co-chairs are Andrew Monte, M.D., and Arjun Chanmugam, M.D.,

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

Puff Puff Post

SEPTEMBER 16, 2019

16, 2019 /CNW/ – Québec doctors have a new tool at their disposal for learning about medical cannabis and its viability as a treatment option for their patients. The program will be offered for free to Québec physicians and is made possible by an unrestricted educational grant from Spectrum Therapeutics.

Programs 40

Programs Research and Development Education Treatment 40

Cannabis Law Report

MAY 29, 2022

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] Clinical Trials and Human Subject Protections. For the regulated community, this is a trend worth watching.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. The MDMA Therapy Training Program was created to train the next generation of psychedelic therapists.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

DECEMBER 21, 2021

This UK-based company caught our attention in 2021 for its team of renowned psychedelic researchers, including chief research officer Professor David Nutt, chief medical officer Dr. Ben Sessa, and head of ketamine psychotherapy Dr. Celia Morgan, as well as its unique studies into ketamine treatment for addiction and gambling addiction.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

Cannabis Law Report

JANUARY 12, 2022

According to a recent report released by the Psychedelic Science Funders Collaborative, “Oregon’s psilocybin therapy program provides a high-quality model for psychedelic healing in a non-prescription context that could be replicated in other states.”

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Cannabis Law Report

JANUARY 13, 2020

In particular, we see significant market opportunity for nabiximols in several indications in the US and will be progressing multiple late stage clinical programs in 2020.”. Commence clinical program to expand future label to include spasticity associated with Spinal Cord Injury. Commence clinical program in PTSD.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

JULY 29, 2021

Tetra Bio-Pharma ( TSX: TBP ) ( OTCQB: TBPMF ) ( FRA:JAM1 ) is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

NOVEMBER 29, 2021

In short: IMO COMPASS Pathway is one of the most undervalued & impactful biotech stocks out there – and atai is committed to being the global leader in novel mental health treatments. We think the COMPASS Phase 2b trial for Treatment-Resistant Depression (TRD) is a total game-changer. Published on November 30, 2021.

Treatment 52

Treatment Clinical Trials Data Patients 52

Cannabis Law Report

NOVEMBER 19, 2021

MAPS PBC is pioneering a new form of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for PTSD. MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD.

Research and Development 52

Research and Development Clinical Trials Therapy Pharmaceutical 52

Veriheal

AUGUST 31, 2020

Essay: “Integrating Research and Medicine: Cannabis Related Treatment for Neurodegenerative Diseases”. Program between St. Essay Summary: Nishtha wants to further research into THC treatment for patients suffering from neurodegenerative diseases like Alzheimer’s and epilepsy , both of which cause neuron death.

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The popularity of medical cannabinoids (MCs) treatment is growing, as more countries enable MCs treatment for various indications in adults 1. Metrics details. Introduction. Search strategy.

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

DECEMBER 6, 2021

–(BUSINESS WIRE)–Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced the appointment of Jeff W. Jacobs, Ph.D. as Chief Scientific Officer (CSO). Dr. Jacobs, who most recently served as CSO of Ardelyx, Inc.,

Research and Development 52

Research and Development Supply Chain Clinical Trials Medicine 52

Cannabis Law Report

DECEMBER 2, 2021

Recommendations and rulemaking relating to training and products were placed on an expedited timeline to ensure that facilitators will be trained, and products will be ready for the January 2, 2023, launch of the first state-sponsored psilocybin therapy program in the United States. Conducting Psilocybin Integration (14 Hours).

Law 52

Law Programs Therapy Education 52

Puff Puff Post

NOVEMBER 5, 2019

. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. Most types of epidermolysis bullosa are inherited. About INM-755.

Clinical Trials 8

Clinical Trials Pharmaceutical Cannabinoids Data 8